The Malmberg lab partner in major cancer immunotherapy project
Karl-Johan Malmberg
The Malmberg Lab is one of four partners in project that recently was awarded 31 MSEK to study and develop new technologies for cancer immunotherapy. The constellation is led by Professor Bjorn Onfelt at the Royal Institute of Technology in Sweden.
The team focus on T and NK cells and their interactions with tumor cells in both 2D and 3D models.
“One of the most exciting things with this collaboration is the interdisciplinary collaboration between biologists, clinical scientists and phycisists”, says Kalle Mamberg, who holds a Visiting Professor position at the Karolinska Institute.
The key challenge is to identify the right cells for the job of eliminating tumor cells. Onfelt Lab has developed a microchip screening platform with 30.000 wells measuring 22x22micrometer. The confined area and multiple wells allows visualization and quantification of multiple, serial interactions using advanced confocal microscopy. It holds potential to identify subpopulations of cells with increased killing capacity.
From major journals, first or last author from the Institute for Cancer Research
Kournoutis A, Stenmark H(2026) Sealing and healing: A two-step model for plasma membrane repair Dev Cell, 61(7), 1345-1346 DOI 10.1016/j.devcel.2026.06.011, PubMed 42419281
Kleinauskas A, Canonaco M, Raabe TTH, Ryan E, Juzenas P, Grallert B, Valiraki A, Papakyriakou A, Theodossiou TA(2026) Phenazine Methosulfate Rewires Mitochondrial Redox Circuits to Restore Membrane Potential and ATP Synthesis Under ETC Blockade in Glioblastoma Cells Antioxidants (Basel), 15(6) DOI 10.3390/antiox15060749, PubMed 42352055
Panagopoulos I, Stranger A, Sveen A, Jareid M, Kidd SG, Bischof K, Taskén K, Dørum A, Davidson B, Lothe RA, Skotheim RI, Johannessen B(2026) Fusion gene heterogeneity and kinase enrichment in high-grade serous carcinomas Neoplasia, 79, 101332(in press) DOI 10.1016/j.neo.2026.101332, PubMed 42349107
Poissonnier A, Rugo HS, Horton W, Kim T, DeLuca A, Egeland EV, Cotechini T, Sivagnanam S, Mori M, Yu Y, Park B, Beelen N, Murugan D, Kirchberger N, Kummar S, Mayer IA, Blackwell K, Hwang ES, Coussens LM(2026) CSF1R Inhibition with Chemotherapy Relieves Systemic Immune Suppression in Patients with Metastatic Triple-Negative Breast Cancer and Boosts Anti-PD-1 Efficacy in Transgenic Mammary Tumors Clin Cancer Res, 32(14), 2832-2849 DOI 10.1158/1078-0432.CCR-25-4236, PubMed 41894563
De Nicolo A, Eccles DM, Aaltonen K, Alhopuro P, Ariansen SL, Biancolella M, Caputo SM, Caron O, Cavalli P, Chiang J, Claes KBM, Cuaresma ECS, de la Hoya M, De Pauw A, Díez O, Domínguez-Valentin M, Ehrencrona H, Fjeldvær MK, Fostira F, Francia MBD, Galego-Carro J, Gómez García EB, Hassan NT, Hauke J, Hirasawa Aet al.(2026) Updated ENIGMA recommendations for reporting germline variants in cancer susceptibility genes and their translation into twenty languages J Med Genet(in press) DOI 10.1136/jmg-2026-111498, PubMed 42135054
Nagel R, Kochavi A, Flem-Karlsen K, Adhikary M, Gal-On Y, Klaoudatou MG, Champagne J, Valcanover L, Palashati H, Nielsen MM, Feng X, Körner PR, Giebel L, Yang W, Velds A, Hoekman L, Bleijerveld OB, van Tellingen O, Olweus J, Agami R(2026) Arginine Deprivation of ASS1-Deficient Cancers Drives Mistranslation and Shared Neoepitope Production Cancer Res, 86(14), 3480-3501 DOI 10.1158/0008-5472.CAN-25-4773, PubMed 42095547